StockpollyBeta
Get App

Categories·Biotech·New Drug Development

Stem Cell Biopharmaceuticals

+2.03% today·34 stocks

Stocks

By market cap · 34 stocks

  1. 1PTCTPTC TherapeuticsRare-disease drugmaker spanning PKU, DMD, and gene therapy$5.45B+1.06%
  2. 2LEGNLegend Biotech (ADR)CARVYKTI commercializer and CAR-T developer$3.43B+0.59%
  3. 3PGENPrecigenPAPZIMEOS commercial-stage gene and cell therapy developer$2.75B+2.39%
  4. 4MESOMesoblast (ADR)Developer of allogeneic cell medicines$2.01B+2.95%
  5. 5IMCRImmunocore (ADR)ImmTAX therapy developer and KIMMTRAK marketer$1.64B+0.81%
  6. 6GLUEMonte Rosa TherapeuticsMolecular glue degrader drug developer$1.04B+2.85%
  7. 7SLBTSL SciencePreclinical immune-cell therapies and Taiwan exosome products$964.5M−2.33%
  8. 8SLDBSolid BiosciencesGene therapies for rare muscle and cardiac diseases$840.8M+4.27%
  9. 9DSGNDesign TherapeuticsGeneTAC developer for inherited genetic diseases$783.8M+4.86%
  10. 10MDXGMiMedxMaker of placental-tissue allografts for wound care$701.1M+2.60%
  11. 11PROKProKidneyAutologous cell therapy developer for advanced kidney disease$596.9M+2.82%
  12. 12PRMEPrime MedicinePrime Editing genetic therapy developer$576.2M+11.13%
  13. 13CAPRCapricor TherapeuticsDeramiocel-focused DMD cell-therapy developer$511.8M+5.00%
  14. 14KYTXKyverna TherapeuticsAutologous CAR-T developer for autoimmune diseases$432.9M+5.62%
  15. 15ARTVArtiva BiotherapeuticsDeveloper of off-the-shelf NK-cell therapies$382.8M+3.38%
  16. 16FATEFateOff-the-shelf iPSC CAR T/NK pipeline$294.9M+2.37%
  17. 17TRDAEntrada TherapeuticsDeveloper of exon-skipping therapies for Duchenne muscular dystrophy$257.8M+1.20%
  18. 18LCTXLineage Cell TherapeuticsDeveloper of allogeneic cell-replacement therapies$251.8M+2.97%
  19. 19NAGENiagen BioscienceNAD+ science and Niagen supplements$242.1M+1.64%
  20. 20RNACCartesian TherapeuticsmRNA cell therapy developer for autoimmune disease$233.3M+2.02%
  21. 21MXCTMaxCyteFlow electroporation cell-engineering platform$130.7M+1.64%
  22. 22ATRAAtara BiotherapeuticsPartner-led EBV-targeted T-cell therapy support$84.5M−4.80%
  23. 23CELUCelularityPlacenta-derived cellular-medicine platforms$35.9M−4.44%
  24. 24MRKRMarker TherapeuticsMulti-antigen T-cell therapies for cancer$20.0M+1.67%
  25. 25GNTAGenenta Science (ADR)Tumor-targeted gene therapy and Italian industrial investments$13.0M+0.44%
  26. 26MSLESatellos BioscienceOral muscle-repair therapy developer for Duchenne muscular dystrophy$11.8M−1.96%
  27. 27ENLVEnlivexAllocetra cell therapy and RAIN treasury$11.7M−8.08%
  28. 28PLURPluriCell-expansion platform for therapies and cultivated foods$11.5M+3.74%
  29. 29GDTCCytoMed TherapeuticsDeveloper of off-the-shelf cancer cell therapies$11.5M−6.19%
  30. 30KALAKALA BIOBiotech AI platform and retained biologics assets$10.8M+6.96%
  31. 31LGVNLongeveronDeveloper of laromestrocel cell therapy$7.5M+11.02%
  32. 32XBIOXenetic BiosciencesDeveloper of DNase cancer-treatment adjuncts$6.9M−14.05%
  33. 33BRTXBioRestorative TherapiesAutologous cell therapy developer for chronic disc disease$3.7M−1.48%
  34. 34CELZCreative Medical TechnologyDeveloper of regenerative cell therapies and CaverStem kits$2.6M−8.46%